Method for rapid detection and identification of bioagents in epidemiological and forensic investigations

• US 8,815,513 B2
• Filed: 10/31/2007
• Issued: 08/26/2014
• Est. Priority Date: 03/02/2001
• Status: Expired due to Fees

• Current Assignee: Ibis Biosciences Incorporated (Abbott Laboratories)
• Original Assignee: Ibis Biosciences Incorporated (Abbott Laboratories)
• Inventors: Ecker, David J., Griffey, Richard H., Sampath, Rangarajan, Hofstadler, Steven A., McNeil, John, Crooke, Stanley T., Hannis, James C.
• Primary Examiner(s): WOOLWINE, SAMUEL C
• Application Number:
  US11/930,741
• Publication Number:
  US 20120171679A1
• Time in Patent Office: 2,491 Days
• Field of Search: None
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/6813 Hybridisation assays
• CPC Class Codes: C12Q 1/6858 Allele-specific amplification
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: C12Q 1/6888 for detection or identification of organisms
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: C12Q 2545/113 with an external standard/control, i.e. control reaction is separated from the test/target reaction
• CPC Class Codes: C12Q 2563/167 Mass label
• CPC Class Codes: C12Q 2565/627 being a mass spectrometer
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention provides methods for rapid forensic investigations by identification of bioagents associated with biowarfare and acts of terrorism or crime. The methods are also useful for epidemiological investigations by genotyping of bioagents.

Claims

1. A method of identifying multiple different etiologic bioagents of a disease or condition, comprising:

a) contacting nucleic acid from said multiple different etiologic bioagents of a disease or condition with two or more oligonucleotide primers that hybridize to sequence regions of said nucleic acid from said multiple different etiologic bioagents of a disease or condition that are conserved among different bioagents, wherein said conserved sequence regions flank variable sequence regions to produce two or more amplification products;

b) determining the base compositions of said two or more amplification products; and

c) identifying said multiple different etiologic bioagents of a disease or condition by comparing said determined base compositions to a database of base compositions comprising nucleic acid numbers but not nucleic acid sequences from a plurality of different bioagents.

2. The method of claim 1, wherein at least one of said multiple different etiologic bioagents of a disease or condition is selected from the group of bioagents consisting of a viral bioagent, a bacterial bioagent, a fungal bioagent, a protozoal bioagent, and a parasitic bioagent.

3. The method of claim 1, wherein at least one of said multiple different etiologic bioagents of a disease or condition is selected from the group of bioagents consisting of a living bioagent, a dead bioagent, and an engineered bioagent.

4. The method of claim 1, wherein at least one of said multiple different etiologic bioagents of a disease or condition is not previously known to exist.

5. The method of claim 1, wherein said multiple different etiologic bioagents of a disease or condition are identified in a human sample.

6. The method of claim 5, wherein said human sample is selected from the group consisting of a body fluid sample, a urine sample, a blood sample, a stool sample, a saliva sample, a tear sample, a mucus sample, a sweat sample, a culture swab sample, a tissue sample, a forensic sample, a skin sample, a hair sample, a nail sample, a clothing sample, an environmental sample, a living sample, a post-mortem sample, and a bio-warfare sample.

7. The method of claim 5, wherein said sample comprises two or more bioagents of different genus, and wherein said nucleic acid from said sample is contacted with two or more oligonucleotide primers configured to differentiate two or more bioagents of different genus.

8. The method of claim 5, wherein said sample comprises two or more bioagents of different species, and wherein said nucleic acid from said sample is contacted with two or more oligonucleotide primers configured to differentiate two or more bioagents of different species.

9. The method of claim 1, further comprising purifying said nucleic acid prior to production of said amplification product.

10. The method of claim 1, wherein said nucleic acid is selected from the group consisting of genomic DNA, RNA, DNA that is complementary to RNA, double-stranded DNA, single stranded DNA, cytoplasmic DNA and extracellular DNA.

11. The method of claim 1, wherein a non-templated T residue on the 5′

-end of at least one of said two or more oligionucleotide primers is removed.

12. The method of claim 1, wherein at least one of said two or more oligonucleotide primers comprises at least one molecular mass modifying tag.

13. The method of claim 1, wherein at least one of said two or more oligonucleotide primers comprises at least one modified nucleobase.

14. The method of claim 13, wherein said modified nucleobase is a propynylated pyrimidine.

15. The method of claim 13, wherein said modified nucleobase is a mass modified nucleobase.

16. The method of claim 13, wherein said modified nucleobase is a universal nucleobase.

17. The method of claim 16, wherein said universal nucleobase is inosine.

18. The method of claim 1, wherein said multiple different etiologic bioagents of a disease or condition are identified at the genus, species, sub-species, strain, sub-type, or nucleotide polymorphism levels.

19. The method of claim 1, wherein said two or more oligonucleotide primers comprise multiple oligonucleotide primer sets configured for differentiation of diverse bioagents.

20. The method of claim 1, wherein said conserved sequence regions are within a gene.

21. The method of claim 1, wherein said conserved sequence regions are within a coding region of a gene.

22. The method of claim 1, wherein said conserved sequence regions are within a regulatory region of a gene.

23. The method of claim 1, wherein said variable sequence regions are within a gene.

24. The method of claim 1, wherein said variable sequence regions are within a coding region of a gene.

25. The method of claim 1, wherein said variable sequence regions are within a regulatory region of a gene.

26. The method of claim 1, wherein said variable sequence regions are about 30-1000 nucleobases in length.

27. The method of claim 1, wherein said two or more amplification products are produced by polymerase chain reactions.

28. The method of claim 1, further comprising purifying said two or more amplification products.

29. The method of claim 1, wherein said base compositions are determined by mass spectrometry.

30. The method of claim 29, wherein said mass spectrometry is ESI mass spectrometry.

31. The method of claim 1, wherein said base compositions of said two or more amplification products comprise identification of the number of A residues, C residues, T residues, G residues, U residues, analogs thereof and/or mass tag residues thereof in said two or more amplification products.

32. The method of claim 1, wherein said base compositions are determined without sequencing said two or more amplification products.

33. The method of claim 1, wherein said comparing comprises identifying a match between said determined two or more base compositions and at least one entry within said database of base compositions from a plurality of different bioagents.

34. The method of claim 1, wherein said identifying said multiple different etiologic bioagents of a disease or condition requires two or more oligonucleotide primer pairs.

35. The method of claim 1, wherein said database of base compositions from a plurality of different bioagents comprises base compositions of genus specific amplification products, family specific amplification products, species specific amplification products, strain specific amplification products, sub-type specific amplification products, or nucleotide polymorphism specific amplification products produced with said two or more oligonucleotide primers, wherein one or more matches between said determined base composition of said amplification product and one or more entries in said database identifies said multiple different etiologic bioagents of a disease or condition, classifies a major classification of said multiple different etiologic bioagents of a disease or condition, or differentiates between subgroups of known and unknown said multiple different etiologic bioagents of a disease or condition.

36. The method of claim 1, wherein said database of base compositions comprises base composition information for at least 3 different bioagents.

37. The method of claim 1, wherein said database of base compositions comprises base composition information for at least 4 different bioagents.

38. The method of claim 1, wherein said database of base compositions comprises base composition information for at least 8 different bioagents.

39. The method of claim 1, wherein said database of base compositions comprises base composition information for at least 19 different bioagents.

40. The method of claim 1, wherein said database of base compositions comprises base composition information for at least 30 different bioagents.

41. The method of claim 1, wherein said database of base compositions comprises at least 12 unique base compositions.

42. The method of claim 1, wherein said database of base compositions comprises at least 40 unique base compositions.

43. The method of claim 1, wherein said database of base compositions comprises base composition information for a bioagent from two or more genuses selected from the group consisting of Acinetobacter, Aeromonas, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Burkholderia, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Coxiella, Enterococcus, Escherichia, Francisella, Fusobacterium, Haemophilus, Helicobacter, Klebsiella, Legionella, Leptospira, Listeria, Moraxella, Mycobacterium, Mycoplasma, Neisseria, Proteus, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptobacillus, Streptomyces, Treponema, Ureaplasma, Vibrio, or Yersinia.

44. The method of claim 1, wherein said database of base compositions comprises base composition information for a bioagent from each of the genuses of Acinetobacter, Aeromonas, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Burkholderia, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Coxiella, Enterococcus, Escherichia, Francisella, Fusobacterium, Haemophilus, Helicobacter, Klebsiella, Legionella, Leptospira, Listeria, Moraxella, Mycobacterium, Mycoplasma, Neisseria, Proteus, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptobacillus, Streptomyces, Treponema, Ureaplasma, Vibrio, or Yersinia.

45. The method of claim 1, wherein said database of base compositions comprises base composition information for a bioagent from two or more orders or families selected from the group consisting of Smallpox virus, Arenavirus, Bunyaviruses, Mononegavirales, Picornaviruses, Astroviruses, Calciviruses, Nidovirales, Flaviviruses, and Togaviruses.

46. The method of claim 1, wherein said database of base compositions comprises base composition information for a bioagent from each of the orders or families of Smallpox virus, Arenavirus, Bunyaviruses, Mononegavirales, Picornaviruses, Astroviruses, Calciviruses, Nidovirales, Flaviviruses, and Togaviruses.

47. The method of claim 1, wherein said base compositions in said database are associated with bioagent identity.

48. The method of claim 1, wherein said base compositions in said database are associated with bioagent geographic origin.

49. The method of claim 1, wherein said comparing step is performed by a computer.

50. The method of claim 49, wherein said computer identifies a match between said determined base composition of said amplification product and one or more entries in database of base compositions from a plurality of different bioagents with a probability algorithm.

51. The method of claim 1, wherein said database is stored on a computer.

52. The method of claim 51, wherein said computer is a local computer.

53. The method of claim 51, wherein said computer is a remote computer.

54. The method of claim 1, wherein said identifying multiple different etiologic bioagents of a disease or condition comprises interrogation of said database with two or more different base compositions associated with said multiple different etiologic bioagents of a disease or condition.

55. The method of claim 1, wherein said database of base compositions comprises at least 10 base compositions.

56. The method of claim 1, wherein said database of base compositions comprises at least 20 base compositions.

57. The method of claim 1, wherein said database of base compositions comprises at least 30 base compositions.

58. The method of claim 1, wherein said database of base compositions comprises at least 40 base compositions.

59. The method of claim 1, wherein said database of base compositions comprises at least 50 base compositions.

60. The method of claim 1, wherein said database of base compositions comprises at least 60 base compositions.

61. The method of claim 1, wherein said database of base compositions comprises at least 70 base compositions.

62. The method of claim 1, wherein said database of base compositions comprises at least 80 base compositions.

63. The method of claim 1, wherein said database of base compositions comprises at least 90 base compositions.

64. The method of claim 1, wherein said database of base compositions comprises at least 100 base compositions.

65. The method of claim 1, wherein said database of base compositions comprises at least 500 base compositions.

66. The method of claim 1, wherein said database of base compositions comprises at least 1000 base compositions.

67. The method of claim 1, wherein said multiple different etiologic bioagents of a disease or condition comprises at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 500 or at least 1000 bioagents.

68. The method of claim 1, wherein said multiple different etiologic bioagents of a disease or condition bioagents are identified by kingdom, phylum, class, order, family, genus, species, sub-species, strain, sub-type, or nucleotide polymorphism.

69. The method of claim 1, wherein said multiple different etiologic bioagents of a disease or condition are identified in a mammalian sample.

70. A system, comprising:

a) a nucleic acid amplification component;

b) a base composition determination component;

c) a base composition identification component comprising a database of base compositions comprising nucleic acid numbers but not nucleic acid sequences from a plurality of bioagents wherein said bioagents comprise multiple different etiologic bioagents of a disease or condition.

71. The system of claim 70, further comprising a nucleic acid purification component.

72. The system of claim 71, wherein said nucleic acid purification component comprises one or more buffer manipulations, one or more salt manipulations, one or more thermal manipulations, one or more pH manipulations, one or more mechanical manipulations, one or more centrifugation manipulations, or one or more magnetic manipulations.

73. The system of claim 70, wherein said nucleic acid amplification component comprises a thermocycler.

74. The system of claim 70, wherein said nucleic acid amplification component comprises one or more salts, one or more buffers, one or more purified oligonucleotide primers, one or more dNTPs, or one or more enzymes.

75. The system of claim 70, wherein said base composition identification component comprises a mass spectrometer.

76. The system of claim 75, wherein said mass spectrometer is an ESI mass spectrometer.

77. The system of claim 70, wherein said base composition identification component comprises a processor.

78. The system of claim 77, further comprising a computer program on a computer readable medium configured to direct said processor to coordinate the operation of said nucleic acid amplification component, said base composition determination component, and said base composition identification component.

79. The system of claim 77, wherein said processor is configured to process mass spectrometry data to base composition data.

80. The system of claim 77, wherein said processor is configured to process base composition data to identify multiple different etiologic bioagents of a disease or condition.

81. The system of claim 70, wherein said database of base compositions comprises at least 10 base compositions.

82. The system of claim 70, wherein said database of base compositions comprises at least 20 base compositions.

83. The system of claim 70, wherein said database of base compositions comprises at least 30 base compositions.

84. The system of claim 70, wherein said database of base compositions comprises at least 40 base compositions.

85. The system of claim 70, wherein said database of base compositions comprises at least 50 base compositions.

86. The system of claim 70, wherein said database of base compositions comprises at least 60 base compositions.

87. The system of claim 70, wherein said database of base compositions comprises at least 70 base compositions.

88. The system of claim 70, wherein said database of base compositions comprises at least 80 base compositions.

89. The system of claim 70, wherein said database of base compositions comprises at least 90 base compositions.

90. The system of claim 70, wherein said database of base compositions comprises at least 100 base compositions.

91. The system of claim 70, wherein said database of base compositions comprises at least 500 base compositions.

92. The system of claim 70, wherein said database of base compositions comprises at least 1000 base compositions.

93. The system of claim 70, wherein said plurality of bioagents comprises bioagents that differ by genus, species, sub-species, strain, sub-type or nucleotide polymorphism.

94. The system of claim 70, wherein said plurality of bioagents comprises one or more viral bioagents, one or more bacterial bioagents, one or more fungal bioagents, one or more protozoal bioagents, one or more parasitic bioagents, one or more mammalian carrier bioagents, or one or more human carrier bioagents.